myelodysplastic syndrome therapeutics

1. Myelodysplastic Syndrome Therapeutics - PipelineAssessment and Market Forecasts to 2017

2. The Myelodysplastic Syndrome Therapeutics Market is Forecast to Show Moderate Growth until 2017 GlobalData estimates that the global myelodysplastic syndrome (MDS) market was valued at $652.6m in 2010 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 12.2% to reach $1.5 billion by 2017. This growth forecast is primarily attributed to the currently approved drugs reaching their peak sales during the forecast period and secondarily due to a strong pipeline. The existing market is strong although with high unmet need. The market is represented by three approved drugs Vidaza (azacitidine), Dacogen (decitabine) and Revlimid (lenalidomide). Unmet Need Continues to Challenge the Pipeline Drugs GlobalData has found that the myelodysplastic syndrome market has high unmet needs, which implies that the market is not well served by the current products in terms of efficacy and safety, and that there is high potential for new entrants. MDS therapies are largely chemotherapeutic agents that are given intravenously. Revlimid is taken as oral tablets. Thus ease of administration also adds to the unmet need present in the market. In summary, the MDS market is expected to be a relatively open market for new entrants until 2017 with many opportunities for value capture. Phase III Pipeline Candidates Provide Modest Hope for Myelodysplastic Syndrome Treatment Paradigm

3. A strong pipeline with 40 molecules in various phases of clinical development, including 37 first-in-class molecules will not significantly drive the market in the forecast period. This is because the Phase III molecules that would be launched in the forecast period are primarily being studied as conditioning therapy prior to bone marrow transplant and are not likely to have much impact on the market. The Phase II first in class molecules are not likely to hit the market during the forecast period. Some of these first-inclass molecules have a distinct advantage over the currently marketed products for MDS in terms of providing better efficacy. The pipeline includes HDCA (Histone deacetylase inhibitors) inhibitors, anti– CD33 mAb (monoclonal antibody) and VEGF (vascular endothelial growth receptor) inhibitors. Most of the clinical trials are being sponsored by companies and are in Phase II stage of development so they are not expected to affect the future MDS therapeutic market significantly in the forecast period For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Myelodysplastic-Syndrome-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017 Visit our report store: http://www.globaldata.com

4. For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782